Marksans Pharma has informed that the shareholders of the Company at the 27th Annual General Meeting (AGM) held on 26th September, 2019 has adopted the Standalone and Consolidated Audited Financial Statements of the Company for the financial year ended 31st March, 2019 together with the reports of the Board of Directors and the Auditors thereon; declared dividend of Rs 0.05 (i.e. 5%) on Equity Shares of Re 1 each face value and dividend of Rs 7.00 (i.e. 7%) on Redeemable Cumulative Preference Shares of Rs 100 each face value. The dividend will be paid on or after 4rd October, 2019; approved re-appointment of Sandra Saldanha (DIN: 00021023), who retired by rotation and being eligible, offered herself for re-appointment; approved appointment of Abhinna Sundar Mohanty (DIN: 00007995) as an Independent Director of the Company for a period of 5 consecutive years with effect from 11th July, 2019; and approved Marksans Employees Stock Option Scheme 2019.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: